X4 Pharmaceuticals (NASDAQ:XFOR) initiated a Phase 1b trial of mavorixafor in combination with ibrutinib, a Burton tyrosine kinase (BTK) inhibitor, for the treatment of Waldenström’s macroglobulinemia (WM). WM is a rare...
Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported topline data from its Phase 3 study of sotagliflozin for the treatment of Type 2 diabetes (T2D). Sotagliflozin is an oral dual inhibitor of sodium-glucose co-transporter...
Aravive (NASDAQ:ARAV) has begun enrolling patients in its Phase 2a clinical trial of AVB-500 in patients with kidney fibrosis, specifically immunoglobulin A nephropathy (IgAN). IgAN occurs when an antibody called...
Arrowhead Pharma (NASDAQ:ARWR) dosed the first patient in its Phase 2 clinical study of ARO-AAT for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated liver disease. AATD is a rare genetic disorder where...
Concert Pharmaceuticals (NASDAQ:CNCE) completed its open-label trial comparing once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial or...
Selecta Biosciences (NASDAQ:SELB) completed enrollment in its Phase 2 COMPARE trial of SEL-212 for the treatment of chronic refractory gout. SEL-212 is designed to sustain control of serum uric acid (SUA) levels in...
Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 GUARD trial of ADX-2191 for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads...
MacroGenics (NASDAQ:MGNX) submitted a biologics license application (BLA) for margetuximab for the treatment of patients with metastatic HER2-positive breast cancer. The submission is based on the safety and efficacy...
Wow, what an interesting year 2019 has turned out to be!On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and...
Opsens (TSX:OPS; OTCQX:OPSSF) received 510(k) clearance from the FDA to market its diastolic pressure ratio (dPR) algorithm. The algorithm is designed to be used with Opsens’ OptoWire, a coronary guide wire used for...
Independent research conducted at the University of Wisconsin-Madison on Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) translingual neurostimulation for the treatment of chronic symptoms due to mild-to-moderate...
Kane Biotech (TSX-V:KNE) fulfilled its first major order, for $125,000 in bluestem pet oral care products, to its exclusive Chinese distribution partner, Eetoys Pet Products. Kane announced the exclusive distribution...
Avadel Pharmaceuticals (NASDAQ:AVDL) completed enrollment in its pivotal trial assessing FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called REST-ON, enrolled 212...
Pacira BioSciences (NASDAQ:PCRX) reported positive results from its Phase 3 study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries. EXPAREL is a non-opioid, single-dose, long-acting local...
Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated a rolling NDA submission to the FDA for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare...
Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...
Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Research indicates that microbial biofilms may aggravate symptoms associated with...
OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...
Closely-held Soricimed Biopharma updated its peptide-drug conjugate (PDC) program, which enables delivery of a cytotoxic drug payload bound to a targeting peptide directly to receptors that are overexpressed by cancer...
Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the next higher dose of CRV431 in its ongoing Phase 1 multiple ascending dose trial in healthy volunteers. The clinical trial management team determined the 75 mg dosing...